Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Firefly Bio, Inc. for USD 1 billion in cashadding the company's antibody-targeted protein degrader platform to strengthen its preclinical oncology pipeline focused on KRAS-driven solid tumors. The acquisition follows J&J's December 2025 purchase of Halda Therapeutics and reflects the company's growing investment in targeted protein degradation as a next-generation therapeutic modality.
Firefly Bio's Firelink platform is designed to deliver highly selective protein degraders directly to tumor cells via antibody conjugation, combining the tumor-targeting specificity of antibody engineering with the intracellular mechanism of targeted protein degradation (TPD). The platform is intended to improve the therapeutic window of KRAS-directed protein degraders by restricting intracellular payload delivery to antigen-expressing tumor cells, potentially reducing off-target toxicity associated with systemic small-molecule approaches. Assets derived from the platform are described as preclinical candidates, with no clinical-stage programs disclosed.
The transaction, first unveiled in June, is structured as an all-cash acquisition with no disclosed milestone payments, royalties, or contingent value rights. It will be accounted for as an asset acquisition, resulting in an in-process research and development charge of approximately USD 1 billion in Q3 2026. J&J expects the transaction to dilute adjusted operational earnings per share by approximately USD 0.46 in 2026 and approximately USD 0.08 in 2027.